U of T Antibody Engineering Technology Gets a $62-million Boost

Jan 4, 2018
Author: 
Jovana Drinjakovic
Professors Sachdev Sidhu and Jason Moffat

A new therapy that enhances the body’s ability to fight cancer has received a $62-million (USD) boost thanks to U of T’s antibody engineering technology.

Called Myeloid Tuning™, the therapy is designed to boost the body’s anti-tumour immunity by removing the cells that normally put brakes on the immune system using engineered antibodies from U of T’s Toronto Recombinant Antibody Centre (TRAC).

“Instead of turning on the immune cells directly, you get rid of the cells that are inhibiting the immune cells,” says Professor Sachdev Sidhu. He co-founded TRAC with Professor Jason Moffat as a state-of-the-art antibody engineering platform at the Donnelly Centre for Cellular and Biomolecular Research, where both are faculty members.

Unlike natural antibodies produced by the immune system to fight disease, engineered antibodies can be designed to target any molecule or cell type and are becoming increasingly used in medicine as a new generation of drugs.

The work that led to myeloid tuning started five years ago as a research collaboration between Sidhu and Moffat, both also professors in U of T’s Department of Molecular Genetics, and Professor Max Krummel at the University of California San Francisco (UCSF). Krummel co-invented the first engineered immunotherapy approved in 2011 against skin cancer. Three years later, Sidhu and Krummel co-founded Pionyr Immunotherapeutics in San Francisco to turn their research idea into reality.

“It’s an example of how you can go very quickly, within a few years, from basic research to potential clinical applications,” says Sidhu.

Last month, Pionyr announced it raised $62 million (USD) from investors bringing its total funding to $72 million (USD) raised in two years to develop myeloid tuning into a form in which it can be tested on patients. The funding boost came on the back of promising proprietary data obtained with antibodies created in Toronto. So far, myeloid tuning has been shown to be effective in multiple mouse tumour models.

Built from the ground up in 2010, TRAC has grown into a sought-after technology platform with more than 50 ongoing collaborations worldwide. Besides Pionyr, there’s also Saksin LifeSciences in India, a startup that is turning TRAC antibodies into new medicines for blindness.

“TRAC has established itself as a premier protein engineering platform attracting partnerships and significant research funding from industry,” says Moffat.

Moffat and Sidhu want to see more new drugs developed in Toronto. That is being made possible thanks to additional support from the visionary philanthropist Terrence Donnelly, whose gift 13 years ago helped found the interdisciplinary biomedical research institute that now bears his name. In October, Donnelly announced a new $10-million gift to support research and innovation. That will enable the Donnelly Centre to soon launch a new hub for biotechnology startups that will accelerate translation of its research discoveries into new therapies.

“Pionyr came out of a similar biotech incubator at UCSF. Imagine what we could do if we had one here. We have thousands of high-quality antibodies that are just sitting there waiting to be turned into new drugs,” said Sidhu.

Oct 3 – Dec 12
Introducing Narrative-Based Medicine – Part One
Course | 6:00pm–8:00pm
Oct 16 – Jun 18
CPD Foundations
Workshop/Seminar | 12:00pm–1:30pm
Nov 21 Café Mathématique - Series on Infectious Disease: The Flu, Math, and You
Lecture | 5:00pm–8:00pm
Nov 23 Paediatric Dermatology Update
Conference | 8:00am–4:45pm
Nov 24 Psychopharmacology Conference 2018
Conference | 7:00am–4:00pm
Nov 26 Family and Community Medicine Graduate Studies Info Session
Other | 8:00am–9:00am
Nov 26 Conflict in Interprofessional Life: Interprofessional Education Curriculum Call for Facilitators
Other | 4:00pm–7:00pm

Tweets

UofT Medicine
@uoftmedicine
Some scientists say that fish oil supplements can prevent heart disease, while others say they don’t have any real… https://t.co/QPlFKHhnzv
UofT Medicine
@uoftmedicine
Whether you know it or not, you are working alongside people with mental illness. As a colleague, you can do a lot… https://t.co/EnDHtpz91o
UofT Medicine
@uoftmedicine
Where’s the science on fish oil supplements? Prof Richard Bazinet explores the ongoing debate https://t.co/1RPMHHYAZB

UofTMed Magazine

Cannabis is coming. Are we ready?

Sign up for your free digital copy.
Back to Top